REBYOTA

REBYOTA @ Home Patient Guide: How to Get REBYOTA (fecal microbiota, live-jslm) at Low or No Cost

REBYOTA (fecal microbiota, live-jslm) is the first FDA-approved single-dose fecal microbiota transplant (FMT) to prevent recurrent Clostridioides difficile (C. diff) infection in adults 18 years and older after antibiotic treatment.[3][4] The REBYOTA @ Home program, offered by Ferring Pharmaceuticals, provides this live microbiome therapy at no cost to eligible patients through the REBYOTA Connect Patient Assistance Program (PAP).[1][2][4]

About REBYOTA and Why You Might Need It

C. diff infection causes severe diarrhea and can recur, disrupting lives with repeated antibiotics and hospital stays. REBYOTA restores gut bacteria balance with a single rectal administration, taking just minutes in a doctor's office or healthcare setting.[3][4] Real-world data shows 75% treatment success (no recurrence at 8 weeks) and improvements in quality of life.[3] It's not a vaccine or antibiotic but a targeted microbiome therapy from screened donors.[4]

Approved by the FDA in November 2022, REBYOTA is available via prescription.[4] If recurrent C. diff has you cycling through treatments, this guide explains how Ferring's PAP can make it free for those who qualify.[1][2]

Who Qualifies for the Program?

The REBYOTA Connect PAP targets patients facing financial barriers to access. While exact income thresholds aren't publicly detailed, programs like this typically assist uninsured, underinsured, or low-income individuals meeting federal poverty guidelines (often 400-500% FPL, adjusted yearly).[1][2] Key factors include:

• Age: 18 years or older, matching REBYOTA's indication.[3][4]
• Medical Need: Prescription for preventing rCDI post-antibiotics.[2][4]
• Financial Hardship: Limited or no insurance coverage; inability to pay out-of-pocket.[2]
• U.S. Residency: Generally required for Ferring U.S. programs.[1]

Ferring verifies eligibility case-by-case. No enrollment fees—it's free to apply and participate.[2]

Income Eligibility Breakdown

Specific income limits for REBYOTA PAP aren't listed in available resources, but Ferring's patient assistance follows standard pharmaceutical PAP models. Here's a general table based on common U.S. PAP structures (e.g., 400-500% Federal Poverty Level, or FPL). Confirm exact criteria with your provider or Ferring, as they may adjust.[1][2]

Table uses 2026 estimates; actual PAP may vary. Medicare/Medicaid often ineligible.[2]

Insurance Requirements

REBYOTA PAP is for patients without adequate coverage. If insured, explore REBYOTA CONNECT co-pay assistance first via REBYOTA.com or your provider.[4] Government insurance like Medicare/Medicaid typically disqualifies PAP eligibility, but Ferring offers bridge programs or reimbursements if product is already administered.[2] Commercial insurance denials or high copays may qualify. Prescribers must confirm no other resources available.[2]

Step-by-Step Application Process

1. Consult Your Doctor: Discuss REBYOTA for rCDI prevention. They complete the REBYOTA Direct Prescription Form.[2]
2. Provider Submits Request: Doctor fills form with patient details, insurance status, and administration date. Mark if emergent.[2]
3. Eligibility Review: Ferring/Optum Frontier Therapies verifies finances/insurance. Free product ships to office/site or reimburses post-administration.[2]
4. Approval Notification: Provider informed; product provided at no charge to you.[2]
5. Administration: Single-dose in-office or healthcare setting (not true 'home' self-admin; professional required).[2]

Start at REBYOTA.com or REBYOTAHCP.com. Call Ferring support via provider.[1][4]

Timeline and Delivery

Processing varies; emergent requests prioritized. Expect product shipment to site prior to administration or reimbursement after.[2] Real-world use shows quick access post-2022 launch.[4] Delivery to doctor's office/healthcare settings ensures safe handling of live therapy.[2] Track via provider.

Alternatives if Denied

• REBYOTA CONNECT Co-Pay Program: Reduces out-of-pocket for insured patients.[4]
• Other PAPs: NeedyMeds.org or RxAssist.org list C. diff options.
• Manufacturer Contact: Appeal denials; status changes may requalify.[2]
• Clinical Trials: Search ClinicalTrials.gov for FMT studies.
• Generic Antibiotics: Vancomycin/fidaxomicin for acute CDI, but not preventive like REBYOTA.

Discuss with your doctor.

Important Disclaimer

This guide synthesizes public info as of 2026; programs change. Not medical/financial advice. Consult healthcare provider/Ferring for personalized details. Ferring may terminate assistance anytime; notify of changes.[2] REBYOTA has risks (e.g., transmission concerns); see full Prescribing Info at REBYOTA.com.[3][4] Word count: 962.